

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong under the Companies Ordinance)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

Drug Registration Approval of the Group's Oncology Drug "Imatinib Mesylate Tablet"

The board of directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries (the "**Group**")) announces that "Imatinib Mesylate Tablet" (the "**Product**") developed by the Group has been granted the Drug Registration Approval by the State Food and Drug Administration of the People's Republic of China (the "**PRC**").

Imatinib Mesylate is a tyrosine-kinase inhibitor product that can suppress the activity of Bcr-Abl tyrosine kinase and can be used for treating patients with chronic myelocytic leukemia and malignant gastrointestinal stromal tumor. Imatinib Mesylate was developed by an overseas pharmaceutical company, and was approved by the U.S. FDA in 2002. It is now approved for use in chronic myelocytic leukemia in more than 80 countries around the world, and is also approved for treating malignant gastrointestinal stromal tumor in numerous developed and developing countries.

Currently, there are only imported original drug and generic drug of Imatinib Mesylate produced by two Chinese enterprises available in the PRC. The approval for launch of the Group's Imatinib Mesylate Tablet will further break the monopoly by the imported product and provide an additional choice to leukemia patients.

Imatinib Mesylate Tablet is the Group's third oncology drug approved for production. The Product will further expand the product portfolio of the Group and enhance the Group's development in the oncology area.

By order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 10 November 2014

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. FENG Zhenying, Mr. CHAK Kin Man, Mr. PAN Weidong, Mr. ZHAO John Huan, Mr. WANG Shunlong, Mr. WANG Huaiyu, Mr. LU Jianmin, Mr. WANG Zhenguo and Mr. WANG Jinxu as executive Directors; Mr. LEE Ka Sze, Carmelo as non-executive Director and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Shilin as independent non-executive Directors.